deltatrials
Completed PHASE2 NCT00002914

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM

Sponsor: Eastern Cooperative Oncology Group

Conditions Bladder Cancer Transitional Cell Cancer of the Renal Pelvis and Ureter Urethral Cancer
Interventions piritrexim
Updated 8 times since 2017 Last updated: Jun 20, 2023 Started: Jul 15, 1997 Primary completion: Jun 30, 2001 Completion: Mar 31, 2004

A PHASE2 clinical study on Bladder Cancer and Transitional Cell Cancer of the Renal Pelvis and Ureter, this trial is completed. The trial is conducted by Eastern Cooperative Oncology Group and has accumulated 8 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jul 2023 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jul 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eastern Cooperative Oncology Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Cedar Rapids, United States, Chicago, United States, Cleveland, United States, Danville, United States, Decatur, United States, Des Moines, United States, East Orange, United States, Fargo, United States, Hackensack, United States and 13 more location s